- Home
- MURA
MURA
Mural Oncology plc
as of 12-04-2025 3:12pm EST
$2.03
$0.01
-0.49%
Stocks Nasdaq
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
Chart Type:
Time Range:
| Founded: | 2013 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 36.0M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 224.8K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.95 - $4.74 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered MURA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 8 days ago
AI Recommendation
hold
Model Accuracy: 85.33%
85.33%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Mural Oncology plc (MURA)
Goodman Vicki L
Sell
Chief Medical Officer
MURA Nov 10, 2025
Avg Cost/Share
$2.08
Shares
5,036
Total Value
$10,474.88
Owned After
84,727
SEC Form 4
Cutler Adam D.
Sell
Chief Financial Officer
MURA Nov 3, 2025
Avg Cost/Share
$2.09
Shares
7,148
Total Value
$14,939.32
Owned After
99,290
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Goodman Vicki L | MURA | Chief Medical Officer | Nov 10, 2025 | Sell | $2.08 | 5,036 | $10,474.88 | 84,727 | |
| Cutler Adam D. | MURA | Chief Financial Officer | Nov 3, 2025 | Sell | $2.09 | 7,148 | $14,939.32 | 99,290 |
Latest Mural Oncology plc News
MURA Breaking Stock News: Dive into MURA Ticker-Specific Updates for Smart Investing
GlobeNewswire
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
📊
AI Sentiment
Positive
7/10
GlobeNewswire
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
âž–
AI Sentiment
Neutral
5/10
Compare MURA vs Leading Stocks
See how MURA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MURA Mural Oncology plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.